Volume 13, Issue 7, Pages 666-675 (July 2014) Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial Peter J Kirkpatrick, FMedSci, Carole L Turner, MSc, Christopher Smith, PhD, Prof Peter J Hutchinson, FRCS, Prof Gordon D Murray, PhD The Lancet Neurology Volume 13, Issue 7, Pages 666-675 (July 2014) DOI: 10.1016/S1474-4422(14)70084-5 Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile DSA=digital subtraction angiography. A screening log is a document that records all patients who enter the screening process before consent. The Lancet Neurology 2014 13, 666-675DOI: (10.1016/S1474-4422(14)70084-5) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 2 Distribution of scores on the mRS scale (A) At 6 months. (B) At discharge. mRS=modified Rankin Scale. The Lancet Neurology 2014 13, 666-675DOI: (10.1016/S1474-4422(14)70084-5) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 3 Kaplan-Meier survival curve The Lancet Neurology 2014 13, 666-675DOI: (10.1016/S1474-4422(14)70084-5) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 4 Distribution of scores on the mRS scale at 6 months for patients who were fully compliant to study medication The Lancet Neurology 2014 13, 666-675DOI: (10.1016/S1474-4422(14)70084-5) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 5 Influence of key pre-randomisation characteristics of patients and treatment type on favourable or unfavourable outcome, post-hoc analysis WFNS=World Federation of Neurosurgical Societies. The Lancet Neurology 2014 13, 666-675DOI: (10.1016/S1474-4422(14)70084-5) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 6 Randomised trials measuring neurological outcome at discharge The Lancet Neurology 2014 13, 666-675DOI: (10.1016/S1474-4422(14)70084-5) Copyright © 2014 Elsevier Ltd Terms and Conditions